References
- Shackleton M, Quintana E, Fearon ER, et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009;138(5):822–829.
- Ellis LM, Chang JC, Mani SA. Local insights: discussing the evolving role of cancer stem cells. Cambridge, MA: Boston Biomedical. 2015. Available at: http://www.bostonbiomedical.com/wp-content/uploads/boston-biomedical-local-insights-houston-texas-discussing-the-evolving-role-of-cscs.pdf.
- What are the limitations of targeted cancer therapies? Bethesda, MD: National Cancer Institute (NCI), National Institutes of Health (NIH), 2014. Available at: https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet#q6.
- Wang W, Quan Y, Fu Q, et al. Dynamics between cancer cell subpopulations reveals a model coordinating with both hierarchial and stochastic concepts. PLoS One. 2014;9(1):e84654.
- Chen K, Huang Y, Chen J-L. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin. 2013;34:732–740.
- Dragu DL, Necula LG, Bleotu C, et al. Therapies targeting cancer stem cells: current trends and future challenges. World J Stem Cells. 2015;7(9):1185–1201.
- Borah A, Raveendran S, Rochani A, et al. Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy. Oncogenesis. 2015;4(11):e177.
- Daniele S, Costa B, Zappelli E, et al. Combined inhibition of AKT/mTOR and MDM2 enhances glioblastoma multiforme cell apoptosis and differentiation of cancer stem cells. Sci Rep. 2015;5:9956. article No.
- Takebe N, Miele I, Harris PJ, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015;12(8):445–464.
- http://www.bostonbiomedical.com/
- http://www.verastem.com/
- https://www.macrogenics.com/
- http://www.stemcentrx.com/
- Efferth T. Stem cells, cancer stem-like cells, and natural products. Planta Med. 2012;78(10):935–942.
- Moselhy J, Srinivasan S, Ankem MK, et al. Natural products that target cancer stem cells. Anticancer Res. 2015;35(11):5773–5788.
- Liu J, Wang L, Zhao F, et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS One. 2015;10(9):E0137345.
- Gavai AV, Quesnelle C, Norris D, et al. Discovery of clinical candidate BMS-906024: a potent pan-Notch inhibitor for the treatment of leukemia and solid tumors. ACS Med Chem Lett. 2015;6(5):523–527.
- Justilien V, Fields AP. Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells. Clin Cancer Res. 2015;21(3):505–513.
- Chi-Med. Innovation platform, RNS announcements: initiation of fruquintinib Phase III registration trial in non-small cell lung cancer, Hutchison MediPharma Limited: China. 2015. Available at: http://www.chi-med.com/initiation-fruquintinib-phase-iii-nsclc
- Guzman ML, Swiderski CF, Howard DS, et al. Preclinical induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA. 2002;99(25):16220–16225.
- Brambilla L, Genini D, Laurini E, et al. Hitting the right spot: mechanism of action of OPB-31121, a novel and potent inhibitor of the signal transducer and activator of transcription 3 (STAT3). Mol Oncol. 2015;9(6):1194–1206.
- Boston Biomedical, Inc. Novel methods for treating cancer. CA2936839 (2015).
- Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases. US8299106 (2012).
- Boston Biomedical, Inc. 3-(Aryl or heteroaryl)methylene indolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer. WO2014160401 (2014).
- Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof. US9187454 (2015).
- Board of Regents, The University of Texas System. Identification of cancer stem cell markers and use of inhibitors thereof to treat cancer. US2014275201 (2014).
- Whitehead Institute for Biomedical Research. Selective targeting of cancer stem cells. WO201474805 (2014).
- Tam WL, Lu H, Buikhuisen J, et al. Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell. 2013;24:347–364.
- University of Canberra, Stem cell modulation II. CA2923765 (2015).
- Novartis AG, Substituted indole derivatives. US20130157980 (2013).
- Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof. US20130143875 (2013).
- Vertex Pharmaceuticals, Inc. Aminopyridine kinase inhibitors. US20130137703 (2013).
- The Brigham and Women’s Hospital, Inc. Methods and compositions relating to the treatment of cancer. US2015374692 (2015).
- The Johns Hopkins University. Cancer treatment with gamma-secretase inhibitors. US2014227173 (2014).
- Olsauskas-Kuprys R, Zlobin A, Osipo C. Gamma secretase inhibitors of Notch signaling. Onco Targets Ther. 2013;6:943–955.
- Lewis SJ, Smith AL, Neduvelil JG, et al. A novel series of potent gamma-secretase inhibitors based on a benzobicyclo[4.2.1]nonane core. Bioorg Med Chem Lett. 2005;15(2):373–378.
- Weigel RJ Use of sumoylation inhibitors for treating cancer. WO2014186573 (2014).
- Godavari Biorefineries Ltd. Compounds for eradicating or inhibiting proliferation of cancer stem cells. WO2015136556 (2015).
- Godavari Biorefineries Ltd. Cancer stem cell targeting compounds. WO2015136557.
- Godavari Biorefineries Ltd. Agents for eliminating tumor-initiating cells. WO201497318 (2014).
- The Trustees of Columbia University in the City of New York. Biomarkers, methods and compositions for inhibiting a multi-cancer mesenchymal transition mechanism. US2014228236 (2014).
- Merck Patent GMBH. Anti-IL-1R1 inhibitors for use in cancer. US2014308294 (2014).
- Universite De Geneve. Uses of NANOG inhibitors and related methods. US2014147440 (2014).
- Abetov D, Mustapova Z, Saliev T, et al. Novel small molecule inhibitors of cancer stem cell signaling pathways. Stem Cell Rev. 2015;11(6):909–918.
- Sahu NU, Kharkar PS. Computational drug repositioning: a lateral approach to traditional drug discovery? Curr Top Med Chem. 2016;16(19):2069–2077.
- Teicher BA. Protein kinase C as a therapeutic target. Clin Cancer Res. 2006;12(18):5336–5345.
- Valdespino V, Valdespino PM. Potential of epigenetic therapies in the management of solid tumors. Cancer Manag Res. 2015;7:241–251.
- Azad N, Zahnow CA, Rudin CM, et al. The future of epigenetic therapy in solid tumours-lessons from the past. Nat Rev Clin Oncol. 2013;10:256–266.
- Buoncervello M, Romagnoli G, Buccarelli M. IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer. Oncotarget. 2016;7(18):26361–26373.